ARTICLE | Company News
OncoGenex, Teva deal
May 25, 2015 7:00 AM UTC
The partners completed the termination of a 2009 deal granting Teva exclusive, worldwide rights to develop and commercialize custirsen sodium ( OGX-011), a second-generation antisense inhibitor of ser...